Insider buying
~$201K20K sh @ $10.18
Traded Feb 27, 2025 · filed 1 day later
The CEO of Arcus Biosciences paid $201K out of pocket for Arcus Biosciences shares. 2 other people at Arcus Biosciences bought some too, in the same month.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
3 tracked managers disclosed the same change for Q4 2024. From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Reduced
Compared with the manager's Q3 2024 13F
663,603
576,156
−13.2%
Share count drives classification; reported value also moves with price
0.29%
Within the filing's reported positions, not the manager's total assets
3
For Q4 2024
Insider buying
Traded Feb 27, 2025 · filed 1 day later
The CEO of Arcus Biosciences paid $201K out of pocket for Arcus Biosciences shares. 2 other people at Arcus Biosciences bought some too, in the same month.
Insider buying
Traded Feb 27, 2025 · filed 1 day later
An Arcus Biosciences director paid $201K out of pocket for Arcus Biosciences shares. 2 other people at Arcus Biosciences bought some too, in the same month. Shares held went up 238% with this purchase.
Insider buying
Traded Feb 18, 2025 · filed 3 days later
A major shareholder of Arcus Biosciences paid $15M out of pocket for Arcus Biosciences shares. 2 other people at Arcus Biosciences bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.